CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Pacific Biosciences Q3 revenue slightly beats expectations on SPRQ-Nx adoption

By Reuters News


Overview

  • Life science sequencing tech firm's Q3 revenue was a slight beat versus analyst expectations

  • Adjusted loss per share for Q3 beat analyst expectations

  • Non-GAAP gross margin declined due to higher memory and Vega transition costs


Outlook

  • PacBio expects 2026 revenue between $155 mln and $160 mln

  • Company sees growing clinical adoption and collaborations expanding addressable markets

  • Company notes higher memory costs and Vega transition may impact margins


Result Drivers

  • SPRQ-Nx ADOPTION - Co said increased SPRQ-Nx adoption drove Revio consumables revenue and software upgrades

  • VEGA SYSTEM SALES - Co delivered 35 new Vega systems, mostly to new customers, and launched SPRQ-Nx for Vega

  • GENEDX PARTNERSHIP - Co said partnership with GeneDx is expected to expand clinical and rare disease work


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$40.60 mln

$40.39 mln (8 Analysts)

Q3 Adjusted Loss Per Share

Beat

$0.11

$0.15 (6 Analysts)

Q3 Loss Per Share

$0.12

Q3 Adjusted Net Loss

Beat

$32.80 mln

$40.78 mln (6 Analysts)

Q3 Adjusted Gross Margin

36.00%

Q3 Adjusted Gross Profit

$14.60 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Pacific Biosciences of California, Inc. is $3.00, about 23% above its November 3 closing price of $2.44


Reuters Recommended Reads

  • Nov 4 - Charles River Laboratories Q3 revenue beats estimates, lifts 2026 outlook

  • Nov 3 - Life sciences tech firm Waters' Q3 revenue, adjusted EPS beat estimates

  • Nov 4 - Bruker Q3 revenue tops estimates on US academic unit strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.